-c-mudit-mathur-jpg
(c)Mudit Mathur
9 July 2015AsiaYuanqiong Hu

Under pressure: India’s progressive IP policies

India, with its progressive public health policies and patent laws, has long been known as the ‘pharmacy of the developing world’. With good reason: more than 96% of the antiretroviral medicines used to treat HIV purchased by donors for developing country treatment programmes are Indian-sourced generics. At Médecins Sans Frontières (MSF), we rely heavily on Indian generics to support the treatment of more than 200,000 people living with HIV/AIDS.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
31 March 2026   The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Asia
20 March 2026   As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.
Asia
5 February 2026   The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.